Drug Profile
Triciribine - Prescient Therapeutics
Alternative Names: API-2; NSC 154020; NSC 280594; PTX-200 - Prescient Therapeutics; TCN; TCN-P; Tricirbine phosphate monohydrate; VQD-002; VQD-002-ORALLatest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator University of South Florida
- Developer Cahaba Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; Prescient Therapeutics; VioQuest Pharmaceuticals
- Class Ribonucleosides; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Breast cancer; Ovarian cancer
- No development reported Haematological malignancies; Pancreatic cancer; Solid tumours
- Discontinued Cancer; HIV infections
Most Recent Events
- 04 Mar 2024 Prescient Therapeutics completes a phase-I/II trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02930109)
- 17 Jun 2020 Prescient Therapeutics terminates a phase I/II trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) for failure to meet enrolment criteria in the phase II portion of the trial (NCT01697293)
- 31 Dec 2019 Prescient Therapeutics terminated the phase I/II trial in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA due to change in strategic focus (IV) (NCT01690468)